Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III study of BPX-04 for Papulopustular Rosacea

Next Previous
Trial Profile

A Phase III study of BPX-04 for Papulopustular Rosacea

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Minocycline (Primary)
  • Indications Rosacea
  • Focus Therapeutic Use
  • Sponsors BioPharmX Corporation; Trex Wind-down

Most Recent Events

  • 15 Feb 2024 According to Timber Pharmaceuticals media release, Timber Pharmaceuticals has changed its name to Trex Wind-down
  • 26 Jun 2019 New trial record
  • 25 Jun 2019 According to a BioPharmX media release, the secondary endpoint, the proportion of subjects with a two-grade improvement to clear or almost clear on the IGA scale from baseline to week 12 from a Phase IIb study was included to collect sufficient data to design this study with co-primary efficacy endpoints.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top